Rheumatology Advance Access originally published online on September 26, 2006
Rheumatology 2007 46(3):516-518; doi:10.1093/rheumatology/kel336
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Mycophenolate mofetil treatment in resistant myositis
Lupus Research Unit, The Rayne Institute, King's College London School of Medicine at Guy's, King's and St Thomas' Hospitals, St Thomas' Hospital, London.
Correspondence to: Cecilia N. Pisoni, MD, Lupus Research Unit, The Rayne Institute, St Thomas' Hospital, Lambeth Palace Road, London SE1 7EH, UK. E-mail: ceciliapisoni{at}gmail.com
 |
Abstract |
|---|
Objectives. To assess the efficacy and tolerability of mycophenolate mofetil (MMF) in six patients with myositis refractory to conventional immunosuppressive therapy.
Methods. Six patients were identified from hospital notes. All had previously failed to respond to other immunosuppressive treatments. Efficacy was measured as changes in muscle strength, creatine kinase (CK) levels and prednisolone dose.
Results. The mean age of the group was 49.8 ± 9.1 yrs, 6 (100%) were female and Caucasian. Patients had failed to respond to a median of 3 (range 1–3) immunosuppressive drugs. They received MMF for a mean of 22.3 ± 18.9 months with a mean MMF dose of 1.6 ± 0.5 g/day. The mean initial prednisolone dose was 13.7 ± 7.7 mg and the mean follow up dose was 8.5 ± 4.9 mg/day (P = 0.03). CK levels were reduced from mean 2395 IU/l ± 1202.8 to 746.6 ± 555.8 IU/l (P = 0.03).
Conclusion. Our data demonstrate that MMF may be effective in myositis, previously unresponsive to conventional immunosuppressive drugs.
KEY WORDS: Myosistis, Mycophenolate mofetil, Treatment
Submitted 13 June 2006;
revised version accepted 29 August 2006.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  V S Sangle, S R Sangle, and D P D'Cruz Leflunomide as a remission-maintaining therapy in difficult-to-treat dermatomyositis Ann Rheum Dis, May 1, 2008; 67(5): 723 - 723. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Piepers, R. Van den Berg-Vos, W-L. Van der Pol, H. Franssen, J. Wokke, and L. Van den Berg Mycophenolate mofetil as adjunctive therapy for MMN patients: a randomized, controlled trial Brain, August 1, 2007; 130(8): 2004 - 2010. [Abstract] [Full Text] [PDF]
|
|